PortalPublikationenCetuximab every 2 weeks versus standard weekly dosing admini...

Cetuximab every 2 weeks versus standard weekly dosing administration schedule

Standard

Cetuximab every 2 weeks versus standard weekly dosing administration schedule. / Bokemeyer, Carsten; Ciardiello, Fortunato; Dubreuil, Olivier; Guigay, Joel; Kasper, Stefan; Pfeiffer, Per; Pinto, Carmine; Yamaguchi, Kensei; Yoshino, Takayuki; Zielinski, Christoph; Esser, Regina; Tabernero, Josep.

in: FUTURE ONCOL, Jahrgang 20, Nr. 7, 03.2024, S. 393-407.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Bokemeyer, C, Ciardiello, F, Dubreuil, O, Guigay, J, Kasper, S, Pfeiffer, P, Pinto, C, Yamaguchi, K, Yoshino, T, Zielinski, C, Esser, R & Tabernero, J 2024, 'Cetuximab every 2 weeks versus standard weekly dosing administration schedule', FUTURE ONCOL, Jg. 20, Nr. 7, S. 393-407. https://doi.org/10.2217/fon-2023-0282

APA

Bokemeyer, C., Ciardiello, F., Dubreuil, O., Guigay, J., Kasper, S., Pfeiffer, P., Pinto, C., Yamaguchi, K., Yoshino, T., Zielinski, C., Esser, R., & Tabernero, J. (2024). Cetuximab every 2 weeks versus standard weekly dosing administration schedule. FUTURE ONCOL, 20(7), 393-407. https://doi.org/10.2217/fon-2023-0282

Vancouver

Bokemeyer C, Ciardiello F, Dubreuil O, Guigay J, Kasper S, Pfeiffer P et al. Cetuximab every 2 weeks versus standard weekly dosing administration schedule. FUTURE ONCOL. 2024 Mär;20(7):393-407. https://doi.org/10.2217/fon-2023-0282

Bibtex

@article{a2093d44a5a842af8ae0471ca5893937,
title = "Cetuximab every 2 weeks versus standard weekly dosing administration schedule",
abstract = "Cetuximab every 2 weeks (Q2W) dosing schedule is approved by the US FDA and by the Japanese Pharmaceuticals and Medical Devices Agency in patients with metastatic colorectal cancer and squamous cell carcinoma of the head and neck. Phase II trials have found comparable efficacy and safety for the weekly (Q1W) and Q2W schedules, and real-world studies have shown noninferiority of the Q2W compared with the Q1W schedule. Several guidelines recommend cetuximab Q2W administration as an alternative to the Q1W dosing schedule. Cetuximab Q2W can be administered with a Q2W dose of chemotherapy, making it a more convenient option to the Q1W schedule, potentially resulting in reduced costs for administration, increased flexibility for clinical staff and improved patient adherence.",
author = "Carsten Bokemeyer and Fortunato Ciardiello and Olivier Dubreuil and Joel Guigay and Stefan Kasper and Per Pfeiffer and Carmine Pinto and Kensei Yamaguchi and Takayuki Yoshino and Christoph Zielinski and Regina Esser and Josep Tabernero",
year = "2024",
month = mar,
doi = "10.2217/fon-2023-0282",
language = "English",
volume = "20",
pages = "393--407",
journal = "FUTURE ONCOL",
issn = "1479-6694",
publisher = "Future Medicine Ltd",
number = "7",

}

RIS

TY - JOUR

T1 - Cetuximab every 2 weeks versus standard weekly dosing administration schedule

AU - Bokemeyer, Carsten

AU - Ciardiello, Fortunato

AU - Dubreuil, Olivier

AU - Guigay, Joel

AU - Kasper, Stefan

AU - Pfeiffer, Per

AU - Pinto, Carmine

AU - Yamaguchi, Kensei

AU - Yoshino, Takayuki

AU - Zielinski, Christoph

AU - Esser, Regina

AU - Tabernero, Josep

PY - 2024/3

Y1 - 2024/3

N2 - Cetuximab every 2 weeks (Q2W) dosing schedule is approved by the US FDA and by the Japanese Pharmaceuticals and Medical Devices Agency in patients with metastatic colorectal cancer and squamous cell carcinoma of the head and neck. Phase II trials have found comparable efficacy and safety for the weekly (Q1W) and Q2W schedules, and real-world studies have shown noninferiority of the Q2W compared with the Q1W schedule. Several guidelines recommend cetuximab Q2W administration as an alternative to the Q1W dosing schedule. Cetuximab Q2W can be administered with a Q2W dose of chemotherapy, making it a more convenient option to the Q1W schedule, potentially resulting in reduced costs for administration, increased flexibility for clinical staff and improved patient adherence.

AB - Cetuximab every 2 weeks (Q2W) dosing schedule is approved by the US FDA and by the Japanese Pharmaceuticals and Medical Devices Agency in patients with metastatic colorectal cancer and squamous cell carcinoma of the head and neck. Phase II trials have found comparable efficacy and safety for the weekly (Q1W) and Q2W schedules, and real-world studies have shown noninferiority of the Q2W compared with the Q1W schedule. Several guidelines recommend cetuximab Q2W administration as an alternative to the Q1W dosing schedule. Cetuximab Q2W can be administered with a Q2W dose of chemotherapy, making it a more convenient option to the Q1W schedule, potentially resulting in reduced costs for administration, increased flexibility for clinical staff and improved patient adherence.

U2 - 10.2217/fon-2023-0282

DO - 10.2217/fon-2023-0282

M3 - SCORING: Review article

C2 - 37850363

VL - 20

SP - 393

EP - 407

JO - FUTURE ONCOL

JF - FUTURE ONCOL

SN - 1479-6694

IS - 7

ER -